Iron Triangle Partners LP Purchases New Stake in West Pharmaceutical Services, Inc. $WST

Iron Triangle Partners LP acquired a new position in West Pharmaceutical Services, Inc. (NYSE:WST) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 70,000 shares of the medical instruments supplier’s stock, valued at approximately $18,363,000. West Pharmaceutical Services accounts for approximately 2.6% of Iron Triangle Partners LP’s investment portfolio, making the stock its 19th biggest position. Iron Triangle Partners LP owned approximately 0.10% of West Pharmaceutical Services as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in WST. Empowered Funds LLC lifted its holdings in West Pharmaceutical Services by 16.1% in the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock valued at $361,000 after buying an additional 224 shares during the period. Intech Investment Management LLC boosted its stake in West Pharmaceutical Services by 27.7% in the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock valued at $1,348,000 after acquiring an additional 1,307 shares during the last quarter. Acadian Asset Management LLC grew its holdings in West Pharmaceutical Services by 14.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after acquiring an additional 157 shares during the period. Savant Capital LLC bought a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at $400,000. Finally, National Pension Service raised its position in shares of West Pharmaceutical Services by 340.4% during the 2nd quarter. National Pension Service now owns 1,198 shares of the medical instruments supplier’s stock valued at $262,000 after acquiring an additional 926 shares during the last quarter. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Trading Up 2.0%

NYSE WST opened at $235.66 on Monday. West Pharmaceutical Services, Inc. has a one year low of $187.43 and a one year high of $322.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.02 and a quick ratio of 2.34. The firm has a market cap of $16.99 billion, a P/E ratio of 34.71, a P/E/G ratio of 2.50 and a beta of 1.17. The stock’s 50-day moving average is $249.85 and its 200-day moving average is $261.96.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.21. The business had revenue of $805.00 million during the quarter, compared to analysts’ expectations of $795.70 million. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.West Pharmaceutical Services’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Wednesday, April 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 12.96%.

West Pharmaceutical Services declared that its board has authorized a stock repurchase program on Tuesday, February 17th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical instruments supplier to repurchase up to 5.6% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

WST has been the topic of several recent research reports. Barclays reduced their price target on West Pharmaceutical Services from $325.00 to $265.00 and set an “equal weight” rating on the stock in a research report on Friday, February 13th. Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Evercore cut their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 price objective on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $314.56.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.